Patent Grant
11298568
The present application generally relates to systems and methods for ablating tissue. More specifically, the present application relates to the treatment of fibrillation or other arrhythmias of the heart by using ultrasound energy, and even more specifically, the present application relates to ablation systems and methods used to treat atrial fibrillation that provide information related to position of the ablation device relative to the tissue, as well as providing information about depth of the lesion and motion of the energy source relative to the tissue.
The condition of atrial fibrillation (AF) is characterized by the abnormal (usually very rapid) beating of the left atrium of the heart which is out of synch with the normal synchronous movement (‘normal sinus rhythm’) of the heart muscle. In normal sinus rhythm, the electrical impulses originate in the sino-atrial node (‘SA node’) which resides in the right atrium. The abnormal beating of the atrial heart muscle is known as ‘fibrillation’ and is caused by electrical impulses originating instead at points other than the SA node, for example, in the pulmonary veins (PV).
There are pharmacological treatments for this condition with varying degree of success. In addition, there are surgical interventions aimed at removing the aberrant electrical pathways from PV to the left atrium (‘LA’) such as the ‘Cox-Maze III Procedure’. This procedure has been shown to be 99% effective but requires special surgical skills and is time consuming. Thus, there has been considerable effort to copy the Cox-Maze procedure using a less invasive percutaneous catheter-based approach. Less invasive treatments have been developed which involve use of some form of energy to ablate (or kill) the tissue surrounding the aberrant focal point where the abnormal signals originate in PV. The most common methodology is the use of radio-frequency (‘RF’) electrical energy to heat the muscle tissue and thereby ablate it. The aberrant electrical impulses are then prevented from traveling from PV to the atrium (achieving the ‘conduction block’) and thus avoiding the fibrillation of the atrial muscle. Other energy sources, such as microwave, laser, and ultrasound have been utilized to achieve the conduction block. In addition, techniques such as cryoablation, administration of ethanol, and the like have also been used.
More recent approaches for the treatment of AF involve the use of ultrasound energy. The target tissue of the region surrounding the pulmonary vein is heated with ultrasound energy emitted by one or more ultrasound transducers.
When delivering energy to tissue, in particular when ablating tissue with ultrasound to treat atrial-fibrillation, a substantially transmural lesion (burning all the way through the tissue) must be made to form a proper conduction block. Achieving a substantially transmural lesion though has many challenges. For example, the physician must insure proper alignment of the energy-delivering device relative to the target tissue. If the energy source is too far away from the tissue, the energy reaching the tissue will be insufficient to create a substantially transmural lesion. If the energy source is too close, the energy may damage the tissue or cause the energy source to overheat. Thus, there is a need for systems and methods that can account for the position of an energy delivery device during ablation of tissue. Moreover, successful ablation is dependent on proper positioning of the ablation device. Because the target tissue can move during ablation (e.g. when ablating tissue in a beating heart), it can also be difficult to create a lesion having the desired depth in the tissue. Additionally the motion of the tissue can result in damage of the tissue, insufficient ablation of the tissue, or damage to the device. Thus there is also a need for improved systems and methods that can accommodate tissue motion during ablation and that can provide information about the depth of the lesion. It would also be desirable to provide an ablation system that is easy to use, easy to manufacture and that is lower in cost than current commercial systems. At least some of these objectives will be met by the disclosure provided herein.
Patents related to the treatment of atrial fibrillation include, but are not limited to the following: U.S. Pat. Nos. 6,997,925; 6,996,908; 6,966,908; 6,964,660; 6,955,173; 6,954,977; 6,953,460; 6,949,097; 6,929,639; 6,872,205; 6,814,733; 6,780,183; 6,666,858; 6,652,515; 6,635,054; 6,605,084; 6,547,788; 6,514,249; 6,502,576; 6,416,511; 6,383,151; 6,305,378; 6,254,599; 6,245,064; 6,164,283; 6,161,543; 6,117,101; 6,064,902; 6,052,576; 6,024,740; 6,012,457; 5,405,346; 5,314,466; 5,295,484; 5,246,438; and 4,641,649.
Patent Publications related to the treatment of atrial fibrillation include, but are not limited to International PCT Publication No. WO 99/02096; and U.S. Patent Publication No. 2005/0267453.
Scientific publications related to the treatment of atrial fibrillation include, but are not limited to: Haissaguerre, M. et al., Spontaneous Initiation of Atrial Fibrillation by Ectopic Beats Originating in the Pulmonary Veins, New England J Med., Vol. 339:659-666; J. L. Cox et al., The Development of the Maze Procedure for the Treatment of Atrial Fibrillation, Seminars in Thoracic & Cardiovascular Surgery, 2000; 12: 2-14; J. L. Cox et al., Electrophysiologic Basis, Surgical Development, and Clinical Results of the Maze Procedure for Atrial Flutter and Atrial Fibrillation, Advances in Cardiac Surgery, 1995; 6: 1-67; J. L. Cox et al., Modification of the Maze Procedure for Atrial Flutter and Atrial Fibrillation. II, Surgical Technique of the Maze III Procedure, Journal of Thoracic & Cardiovascular Surgery, 1995; 110:485-95; J. L. Cox, N. Ad, T. Palazzo, et al. Current Status of the Maze Procedure for the Treatment of Atrial Fibrillation, Seminars in Thoracic & Cardiovascular Surgery, 2000; 12: 15-19; M. Levinson, Endocardial Microwave Ablation: A New Surgical Approach for Atrial Fibrillation; The Heart Surgery Forum, 2006; Maessen et al., Beating Heart Surgical Treatment of Atrial Fibrillation with Microwave Ablation, Ann Thorac Surg 74: 1160-8, 2002; A. M. Gillinov, E. H. Blackstone and P. M. McCarthy, Atrial Fibrillation: Current Surgical Options and their Assessment, Annals of Thoracic Surgery 2002; 74:2210-7; Sueda T., Nagata H., Orihashi K., et al., Efficacy of a Simple Left Atrial Procedure for Chronic Atrial Fibrillation in Mitral Valve Operations, Ann Thorac Surg 1997; 63:1070-1075; Sueda T., Nagata H., Shikata H., et al.; Simple Left Atrial Procedure for Chronic Atrial Fibrillation Associated with Mitral Valve Disease, Ann Thorac Surg 1996; 62:1796-1800; Nathan H., Eliakim M., The Junction Between the Left Atrium and the Pulmonary Veins, An Anatomic Study of Human Hearts, Circulation 1966; 34:412-422; Cox J. L., Schuessler R. B., Boineau J. P., The Development of the Maze Procedure for the Treatment of Atrial Fibrillation, Semin Thorac Cardiovasc Surg 2000; 12:2-14; and Gentry et al., Integrated Catheter for 3-D Intracardiac Echocardiography and Ultrasound Ablation, IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, Vol. 51, No. 7, pp 799-807.
The present application generally relates to systems and methods for ablating tissue. More specifically, the present application relates to the treatment of fibrillation or other arrhythmias of the heart by using ultrasound energy, and even more specifically, the present application relates to ablation systems and methods used to treat atrial fibrillation that provide information related to position of the ablation device relative to the tissue, as well as providing information about depth of the lesion and motion of the energy source relative to the tissue.
In a first aspect of the present invention, a method of ablating tissue in a patient as a treatment for fibrillation comprises providing an ablation device having an energy source and a sensor. The energy source provides a beam of energy directable to target tissue, and the sensor senses energy reflected back from the target tissue. The sensor collects a noise profile of the ablation device. The ablation device is positioned adjacent the target tissue, and an amplitude mode data set that characterizes the target tissue is collected with the sensor. The noise profile is removed from the amplitude mode data set to determine a gap distance between the energy source and the target tissue. The target tissue is ablated with the beam of energy and operating parameters of the ablating step are adjusted in response to the gap distance.
In any aspect of the present invention, the energy source may comprise an ultrasound transducer. Positioning of the ablation device may comprise advancing the ablation device into a left atrium of the heart. The ablating may create a contiguous lesion in the target tissue, and the lesion may block aberrant electrical pathways in the tissue so as to reduce or eliminate the fibrillation. The fibrillation may comprise atrial fibrillation.
The noise profile may comprise an average amplitude value from a set of samples obtained in an echo-less environment. The noise profile may also comprise one of a signal pattern, a frequency band, and a set of signals. The noise profile may comprise electrical noise, backscatter noise of a fluid, or sensor noise. Collecting the noise profile may comprise positioning at least a portion of the ablation device into a fluid and collecting samples, or collection may be performed during calibration of the ablation device. Collecting of the noise profile may further comprise storing the noise profile data.
The amplitude mode data set may be collected continuously or periodically during the ablating, or during a during a diagnostic sweep of the target tissue prior to the ablating. Removing the noise may be repeated continuously or periodically during the ablating.
The method may further comprise using a plurality of gap distances to approximate an incident angle of the beam of energy relative to a surface of the target tissue. Operating parameters of the ablation step may be adjusted in response to the approximated incident angle.
The adjusting may comprise adjusting the power in the beam of energy, or repositioning the energy source relative to the target tissue.
In another aspect of the present invention, a method of ablating tissue in a patient as a treatment for fibrillation comprises providing an ablation device having an energy source and a sensor. The energy source provides a beam of energy directable to target tissue, and the sensor senses energy reflected back from the target tissue. The ablation device is positioned adjacent the target tissue, and data is collected over a surface of the target tissue with the sensor. A map of the tissue is generated and the target tissue is ablated with the beam of energy. The tissue map is used to facilitate execution of the ablation step.
The collecting step may comprise moving the sensor across the target tissue in any pattern, including a zig-zag pattern or a continuous path. Collecting the data may comprise collecting gap distance between the energy source and a surface of the target tissue.
The map may be generated as a part of a diagnostic sweep of the target tissue prior to the ablating step, and the map may identify anatomical structure in the target tissue such as the pulmonary veins. The map may indicate gap distance between the energy source and a surface of the target tissue, or the map may indicate surface contours and angles of the target tissue. The map may comprise a two dimensional or a three dimensional representation of the target tissue.
Use of the tissue map may facilitate generation of an ablation path or adjustment of power in the beam of energy. The map may also facilitate planning of ablation path distances. The map may comprise angles of the energy beam relative to the target tissue, and use of the map may facilitate adjustment of power in the beam of energy based on the angles.
In still another aspect of the present invention, a method of ablating tissue in a patient as a treatment for fibrillation comprises providing an ablation device having an energy source and a sensor. The energy source provides a beam of energy directable to target tissue, and the sensor senses energy reflected back from the target tissue. The ablation device is positioned adjacent the target tissue and a portion of the target tissue is repeatedly scanned. Information about the motion of the target tissue relative to the energy source is calculated. The target tissue is ablated with the beam of energy and the motion is accounted for during the ablation.
The scanning may comprise collecting information about gap distance between the energy source and a surface of the target tissue. The target tissue may comprise tissue in the heart, and the scanning may occur while the heart is beating. Scanning may comprise scanning the target tissue over a short time duration of 5 milliseconds or less. Scanning may comprise repeatedly scanning a single spot.
The calculating may comprise calculating variance, velocity, or acceleration of the target tissue. Accounting for the motion may comprise adjusting the energy beam position or power based on the calculated information. The accounting step may also comprise maintaining gap distance between the energy source and the target tissue within a predetermined range, based on the calculated information. The predetermined range may be from 2 and 20 mm.
The method may further comprise identifying tissue type based on the motion. Sensitive tissue that is unsuitable for ablation may be identified based on the motion. Anatomical structures such as the pulmonary veins may be identified based on the motion. The method may further comprise determining thickness of the target tissue based on the motion.
In yet another aspect of the present invention, a method for of ablating tissue in a patient as a treatment for fibrillation comprises providing an ablation device having an energy source and a sensor. The energy source provides a beam of energy directable to target tissue, and the sensor senses energy reflected back from the target tissue. The ablation device is positioned adjacent the target tissue and a standard lesion ratio from the target tissue is provided. An initial backscatter signal from unablated target tissue is sensed with the sensor and the target tissue is ablated with the beam of energy. A post ablation backscatter signal from the target tissue after ablation is sensed. The current lesion ratio is then compared to the standard lesion ratio, and the ablation is discontinued when the current lesion ratio is greater than or equal to the standard lesion ratio.
The standard lesion ratio may comprise a numerical value associated with a substantially transmural lesion. The standard lesion ratio may comprise a normalized backscatter signal value of a transmural lesion. The standard lesion ratio may also comprise a normalized signal pattern, a frequency, or other unique property of a substantially transmural lesion. Providing the standard lesion ratio may further comprise sensing a tissue backscatter signal in a region of the tissue with high echodensity, sensing a tissue backscatter signal in a region of the tissue with low echodensity, and determining a ratio of the high and the low echodensity backscatter signals. The region of high echodensity may comprise a substantially transmural lesion, and the region of low echodensity may comprise unablated tissue. The standard lesion ratio may comprise a laboratory determined value.
The sensing of the initial backscatter signal may be obtained during a diagnostic sweep of the target tissue prior to ablation thereof, or it may be obtained prior to the ablating, or during the ablating. The ablating may comprise incrementally increasing lesion depth in the ablated tissue. The increments may decrease in value as lesion depth increases or the increments may be of constant value. The ablating may comprise continuously increasing lesion depth in the ablated tissue.
The sensing of the post ablation backscatter signal may occur after each incremental ablation step is performed, or it may occur periodically during the ablation. It may also occur continuously during the ablation. The comparing step may determine if the ablation has created a substantially transmural lesion in the target tissue.
These and other embodiments are described in further detail in the following description related to the appended drawing figures.
The following description of the preferred embodiments of the invention is not intended to limit the invention to these preferred embodiments, but rather to enable any person skilled in the art to make and use this invention.
As shown in
The Energy Source. As shown in
As shown in
As shown in
The energy source 12 is preferably an ultrasound transducer that emits an ultrasound beam, but may alternatively be any suitable energy source that functions to provide a source of ablation energy. Suitable sources of ablation energy include but are not limited to, radio frequency (RF) energy, microwaves, photonic energy, and thermal energy. The therapy could alternatively be achieved using cooled sources (e.g., cryogenic fluid). The energy delivery system 10 preferably includes a single energy source 12, but may alternatively include any suitable number of energy sources 12. The ultrasound transducer is preferably made of a piezoelectric material such as PZT (lead zirconate titanate) or PVDF (polyvinylidine difluoride), or any other suitable ultrasound emitting material. For simplicity, the front face of the transducer is preferably flat, but may alternatively have more complex geometry such as either concave or convex to achieve an effect of a lens or to assist in apodization—selectively decreasing the vibration of a portion or portions of the surface of the transducer—and management of the propagation of the energy beam 20. The transducer preferably has a circular geometry, but may alternatively be elliptical, polygonal, or any other suitable shape. The transducer may further include coating layers which are preferably thin layer(s) of a suitable material. Some suitable transducer coating materials may include graphite, metal-filled graphite, gold, stainless steel, magnesium, nickel-cadmium, silver, and a metal alloy. For example, as shown in
The energy source 12 is preferably one of several variations. In a first variation, as shown in
The inactive portion 42 is preferably a hole or gap defined by the energy source 12′. In this variation, a coolant source may be coupled to, or in the case of a coolant fluid, it may flow through the hole or gap defined by the energy source 12′ to further cool and regulate the temperature of the energy source 12′. The inactive portion 42 may alternatively be made of a material with different material properties from that of the energy source 12′. For example, the material is preferably a metal, such as copper, which functions to draw or conduct heat away from the energy source 12. Alternatively, the inactive portion is made from the same material as the energy source 12, but with the electrode plating removed or disconnected from the electrical attachments 14 and or the generator. The inactive portion 42 is preferably disposed along the full thickness of the energy source 12′, but may alternatively be a layer of material on or within the energy source 12′ that has a thickness less than the full thickness of the energy source 12′. As shown in
In a third variation, as shown in
In a fourth variation, as shown in
The Electrical Attachment. As shown in
The energy delivery system 10 of the preferred embodiments also includes an electrical generator (not shown) that functions to provide power to the energy source 12 via the electrical attachment(s) 14. The energy source 12 is preferably coupled to the electrical generator by means of the suitably insulated wires 38 and 38′ connected to the electrical attachments 14 and 14′ coupled to the two faces of the energy source 12. When energized by the generator the energy source 12 emits energy. The generator provides an appropriate signal to the energy source 12 to create the desired energy beam 20. The frequency is preferably in the range of 5 to 25 MHz, more preferably in the range of 8 to 20 MHz, and even more preferably in the range of 2 to 15 MHz. The energy of the energy beam 20 is determined by the excitation voltage applied to the energy source 12, the duty cycle, and the total time the voltage is applied. The voltage is preferably in the range of 5 to 200 volts peak-to-peak. In addition, a variable duty cycle is preferably used to control the average power delivered to the energy source 12. The duty cycle preferably ranges from 0% to 100%, with a repetition frequency that is preferably faster than the time constant of thermal conduction in the tissue. One such appropriate repetition frequency is approximately 40 kHz.
Energy Beam and Tissue Interaction. When energized with an electrical signal or pulse train by the electrical attachment 14 and/or 14′, the energy source 12 emits an energy beam 20 (such as a sound pressure wave). The properties of the energy beam 20 are determined by the characteristics of the energy source 12, the matching layer 34, the backing 22 (described below), the electrical signal from electrical attachment 14. These elements determine the frequency, bandwidth, and amplitude of the energy beam 20 (such as a sound wave) propagated into the tissue. As shown in
The Physical Characteristics of the Lesion. The shape of the lesion or ablation zone 278 formed by the energy beam 20 depends on the characteristics of suitable combination factors such as the energy beam 20, the energy source 12 (including the material, the geometry, the portions of the energy source 12 that are energized and/or not energized, etc.), the matching layer 34, the backing 22 (described below), the electrical signal from electrical attachment 14 (including the frequency, the voltage, the duty cycle, the length and shape of the signal, etc.), and the characteristics of target tissue that the beam 20 propagates into and the length of contact or dwell time. The characteristics of the target tissue include the thermal transfer properties and the ultrasound absorption, attenuation, and backscatter properties of the target tissue and surrounding tissue.
The shape of the lesion or ablation zone 278 formed by the energy beam 20 is preferably one of several variations due to the energy source 12 (including the material, the geometry, the portions of the energy source 12 that are energized and/or not energized, etc.). In a first variation of the ablation zone 278, as shown in
In a second variation, as shown in
The size and characteristics of the ablation zone also depend on the frequency and voltage applied to the energy source 12 to create the desired energy beam 20. For example, as the frequency increases, the depth of penetration of ultrasound energy into the tissue is reduced resulting in an ablation zone 278 (ref.
The size and characteristics of the ablation zone 278 also depend on the time the targeted tissue is contacted by the energy beam 20, as shown in
The ultrasound energy density preferably determines the speed at which the ablation occurs. The acoustic power delivered by the energy source 12 divided by the cross sectional area of the beam 20 determines the energy density per unit time. Effective acoustic power preferably ranges from 0.5 to 25 watts, more preferably from 2 to 10 watts, and even more preferably from 2 to 7 watts, and the corresponding power densities preferably range from 50 watts/cm2 to 2500 watts/cm2. These power densities are developed in the ablation zone. As the beam diverges beyond the ablation zone, the power density falls such that ablation will not occur, regardless of the time exposure.
Although the shape of the ablation zone 278 is preferably one of several variations, the shape of the ablation zone 278 may be any suitable shape and may be altered in any suitable fashion due to any suitable combination of the energy beam 20, the energy source 12 (including the material, the geometry, etc.), the matching layer 34, the backing 22 (described below), the electrical signal from electrical attachment 14 (including the frequency, the voltage, the duty cycle, the length of the pulse, etc.), and the target tissue the beam 20 propagates into and the length of contact or dwell time.
The Sensor. The energy delivery system 10 of the preferred embodiments also includes a sensor separate from the energy source and/or the energy source 12 may further function as a sensor to detect the gap (the distance of the tissue surface from the energy source 12), the thickness of the tissue targeted for ablation, the characteristics of the ablated tissue, the incident beam angle, and any other suitable parameter or characteristic of the tissue and/or the environment around the energy delivery system 10, such as the temperature. By detecting the information, the sensor (coupled to the processor, as described below) preferably functions to guide the therapy provided by the ablation of the tissue.
The sensor is preferably one of several variations. In a first variation, the sensor is preferably an ultrasound transducer that functions to detect information with respect to the gap, the thickness of the tissue targeted for ablation, the characteristics of the ablated tissue, and any other suitable parameter or characteristic. The sensor preferably has a substantially identical geometry as the energy source 12 to insure that the area diagnosed by the sensor is substantially identical to the area to be treated by the energy source 12. More preferably, the sensor is the same transducer as the transducer of the energy source, wherein the energy source 12 further functions to detect information by operating in a different mode (such as A-mode, defined below).
The sensor of the first variation preferably utilizes a burst of ultrasound of short duration, which is generally not sufficient for heating of the tissue. This is a simple ultrasound imaging technique, referred to in the art as A Mode, or Amplitude Mode imaging. As shown in
In a second variation, the sensor is a temperature sensor that functions to detect the temperature of the target tissue, the surrounding environment, the energy source 12, the coolant fluid as described below, and/or the temperature of any other suitable element or area. The temperature senor is preferably a thermocouple, but may alternatively be any suitable temperature sensor, such as a thermistor or an infrared temperature sensor. This temperature information gathered by the sensor is preferably used to manage the delivery of continuous ablation of the tissue 276 during therapy and to manage the temperature of the target tissue and/or the energy delivery system 10 as discussed below.
The Processor. The energy delivery system 10 of the preferred embodiments also includes a processor 33 (illustrated in
The processor 33 preferably receives information from the sensor such as information related to the gap distance, the thickness of the tissue targeted for ablation, the characteristics of the ablated tissue, and any other suitable parameter or characteristic. Based on this information, the processor preferably controls the energy beam 20 emitted from the energy source 12 by modifying the electrical signal sent to the energy source 12 via the electrical attachment 14 such as the frequency, the voltage, the duty cycle, the length of the pulse, and/or any other suitable parameter. The processor preferably also controls the energy beam 20 by controlling portions of the energy source 12 that are energized using various frequencies, voltages, duty cycles, etc. Different portions of the energy source 12 may be energized as described above with respect to the plurality of annular transducers 44 and the grid of transducer portions 46 of the energy source 12″ and 12″′ respectively. Additionally, the processor may further be coupled to a fluid flow controller. The processor preferably controls the fluid flow controller to increase or decrease fluid flow based on the sensor detecting characteristics of the ablated tissue, of the unablated or target tissue, the temperature of the tissue and/or energy source, and/or the characteristics of any other suitable condition.
By controlling the energy beam 20 (and/or the cooling of the targeted tissue or energy source 12), the shape of the ablation zone 278 is controlled. For example, the depth 288 of the ablation zone is preferably controlled such that a transmural lesion (a lesion through the thickness of the tissue) is achieved. Additionally, the processor preferably functions to minimize the possibility of creating a lesion beyond the targeted tissue, for example, beyond the outer atrial wall. If the sensor detects the lesion and/or the ablation window 2172 (as shown in
Additionally, the processor preferably functions to maintain a preferred gap distance between the energy source and the tissue to be treated. The gap distance is preferably between 2-25 mm, more preferably between 2-20 mm, and even more preferably between 2-15 mm. If the sensor detects the lesion and/or the ablation window 2172 (as shown in
Gap Data Collection Method. As shown in
Step S100, which recites collecting a noise profile of an energy delivery system, functions to collect a set of data that represents the noise signal received during normal measurements. The noise profile is preferably an average amplitude value from a set of samples obtained in an echo-less environment (not during normal operation conditions). The noise profile may also be a signal pattern, a frequency band, a set of signals, or any other parameter that may be recognized as the noise component. During A-mode sampling, the echo component is the desired signal. Thus, by measuring the noise profile, the processor can isolate the echo component (the portion of the signal that has been reflected off a tissue surface) from the data. The noise profile may be a signal composed of electrical noise, backscatter noise of a fluid, sensor/component noise, or any other type of noise or combination of noise signals that are not a part of the echo component.
The step of collecting a noise profile is preferably performed by positioning the energy delivery system 10 in a dish of saline solution and collecting samples. The energy delivery system 10 may alternatively be positioned or held in any suitable solution or material to create or simulate an echoless environment. More preferably, Step S100 is performed during a calibration mode and it includes storing the data as a noise profile. The calibration mode is preferably activated by the user or alternatively may be automatically run prior to operation or activated in any suitable manner. Alternatively, the processor may average a large number of A-mode lines while the energy delivery system 10 is deployed. In this alternative, any return signals from a real target is randomly located and over time would preferably average out to a baseline noise profile. The A-mode lines used for the averaged noise profile may be from a set number of samples during the lifetime use of the energy delivery system, or may alternatively be from an initial calibration sweep performed at the beginning of a procedure.
Step S110, which recites collecting an A-mode data set, functions to collect the normal diagnostic data. Step S110 is preferably repeated continuously or periodically during an ablation process. Step S110 is preferably performed in a manner identical to that described above with respect to the sensor.
Step S120, which recites removing the noise profile component from the A-mode data set, functions to isolate the gap distance signal from the noise. Preferably, the average value of the noise profile is subtracted from the A-mode data set. The result is preferably a signal dependent on the gap distance. Alternatively, if the noise profile component is contained within a certain frequency bandwidth, the processor preferably filters (with, for example, a lowpass, highpass, bandpass, or bandstop filter) the signal to isolate the gap distance signal. Any other suitable signal processing method may be used to isolate the gap distance signal.
Steps S110 and S120 are preferably repeated continuously or periodically during the ablation of tissue. Repeating Steps S110 and S120 functions to collect the gap data during the ablation process so the gap distance may be known at the time of the ablation process. The gap data may alternatively be collected during a diagnostic sweep of the tissue prior to the ablation sweep.
The preferred method to collect noise-reduced gap data may also include using multiple gap distances to approximate incident angle of beam on tissue S130. Step S130 is preferably performed after Step S120. The processor preferably stores gap data taken continuously or periodically during the ablation process or alternatively information stored during a diagnostic sweep prior to the ablation sweep. Preferably, three consecutive or closely spaced gap distances are used to calculate the angle of incidence of the energy delivery system. Alternatively, any suitable number of points may be used. The angle of incidence may be used in further steps to improve the interaction of the ultrasound energy beam with the tissue during the ablation process and, ultimately, create a desired transmural lesion of the tissue.
The preferred method to collect noise-reduced gap data may also include adjusting the settings of the energy delivery system based on gap data S140. Step S140 is preferably performed after Step S130. Step S140 functions to adjust the ablation process to account for fluctuations in gap distance and/or angle and may function to prevent damage to the tissue or the device. Based on the gap distance and/or beam incidence angle, the processor preferably controls the energy beam emitted from the energy source by modifying the electrical signal sent to the energy source via the electrical attachment such as the frequency, the voltage, the duty cycle, the length of the pulse, dwell time, and/or any other suitable parameter. The processor may alternatively reposition the energy delivery device.
Pre-mapping method. As shown in
Step S200, which recites collecting data of the surface of the tissue of interest, functions to move the energy delivery system systematically over the tissue, periodically collecting gap distance data. The energy delivery system is preferably moved over the tissue in a horizontal zig-zag pattern, but the energy delivery system may alternatively be moved over the surface in any suitable pattern that sufficiently captures data for the tissue of interest. The path is preferably a singular continuous path but may alternatively include multiple discontinuous paths to capture tissue features from varying angles. As the energy delivery system moves above the surface of the tissue, the sensor preferably collects gap data using a method similar to that described above.
Step S210, which recites generating a tissue map, functions to generate a computer model of the tissue surface. The computer model is preferably generated using the gap data collected during Step S200 by associating the gap distance with the position of the energy delivery system during the data collection. The model preferably provides relative distance information for the surface. The model may additionally and/or alternatively may be used to interpolate the surface angles and contours. The computer model is preferably represented as a 2D image (to take advantage of image processing techniques), a 3D point cloud, 3D surface, or any other suitable format.
Step S220, which recites using the tissue map to execute the ablation process, functions to predict ablation paths and energy delivery system settings. Step S220 preferably includes the sub-steps finding anatomy features S222, planning ablation path distances S224, and using angle information to adjust energy settings S226.
Sub Step S222, which recites finding anatomy features, functions to identify anatomical structures to obtain the orientation of the energy delivery system within the heart cavity. Preferably, the pulmonary vein is identified as an area that defines a recess in the surface of the model. Alternatively, other anatomical features may be identified by size, shape, or any other suitable characteristic from the tissue map.
SubStep S224, which recites planning ablation path distances, functions to create a route with optimized gap distances that the energy delivery system will move through. The ablation path preferably has circular geometry, but may alternatively be elliptical, polygonal, or any other suitable shape. The gap distances from the tissue for each position are set to an optimal distance for the ablation process, preferably between 2-25 mm, more preferably between 2-20 mm, and even more preferably between 2-15 mm.
SubStep 226, which recites using angle information to adjust energy settings, functions to optimize the beam energy for proper transmural lesions. The processor preferably makes appropriate changes to the frequency, voltage, duty cycle, power, and/or dwell time of the energy delivery system.
Method for Detecting Wall Motion. As shown in
Step S300, which recites scanning a portion of tissue repeatedly over a short time duration, functions to collect sample gap data (the data set of the separation between the tissue and the energy delivery system) during the periodic motion of the heart tissue. Preferably, the sensor interrogates a singular spot of the tissue (or a group of closely spaced points) multiple times during a brief period of time (preferably over the time span of 5 ms or less, based on the necessary Nyquist sampling frequency for a heart rate of 100 beats per minute. The gap data obtained during the interrogation for a static system will generally remain constant, but—in the case of moving tissue—the gap data will generally vary over time. Alternatively, the gap data may be collected during a normal (preferably slow moving) diagnostic scan, where a singular spot is not repeatedly interrogated. In this alternative, closely spaced points are approximated as a single point, and the motion is approximated over the area defined by these points.
Step S310, which recites calculating motion information for the tissue, functions to generate the variance, velocity, and/or acceleration values for the tissue to be used in Step S320. The processor preferably calculates the variance of an A-mode data set, but the processor may calculate the variance on any suitable data. The variance preferably corresponds to the amplitude of the periodic displacement of the tissue. The motion variance is preferably used to position the energy delivery system 10, and set the parameters of the energy beam used for ablation.
Step S320, which recites accounting for tissue motion, functions to alter the position or energy beam settings of the energy delivery system. Step S320 may further function to ensure that a transmural tissue lesion is created during ablation. Preferably, the processor uses the variance of motion calculated in Step S310. The variance is preferably used to position the energy delivery system such that the gap distance is maintained within a suitable gap distance range. The gap distance is preferably maintained preferably between 2 and 25 mm, more preferably between 2 and 20 mm, and even more preferably between 2 and 15 mm. Alternatively, the energy beam may be set to accommodate for the variance in position.
In an alternative embodiment, Steps S310 and S320 may use the velocity and/or acceleration to predict motion. In this alternative, Step S310 preferably includes the calculation of velocity, acceleration, frequency, and/or any other property of the tissue motion. The processor preferably uses the calculated motion parameters and the periodic motion of the heart to predict the gap distance at any given time. In Step 320, knowledge of the exact gap distance is then used to reposition and change the energy beam settings for near optimal tissue ablation.
As an additional step, the method may include identifying tissue type based on tissue motion S330. This step functions to identify sensitive tissue (tissue not to be ablated) or anatomical structures to use as a referential positioning. The processor preferably compares the recorded motion of the tissue to an anatomical model of tissue. The model may be an average variance of motion or may be more fully defined including modeling of surrounding tissue. The tissue velocity, magnitude of motion, motion frequency, or any other suitable characteristic obtained from the motion profile can be used to distinguish different types of tissue. As an example of tissue identification, the atrial wall tends to move much more than the connective tissues around the heart. The processor may distinguish the two types of tissue by the magnitude of motion variance.
As an additional step, the method may further include detecting tissue thickness S340. Step S340 functions to prevent over and under ablation of tissue. The variance of tissue motion corresponds indirectly with tissue thickness (greater variance corresponds to thinner tissue and, in contrast, small variance corresponds to greater thickness). Preferably, the tissue thickness is based on the variance of tissue motion. Alternatively, the mechanical properties of average tissue such as stiffness are known and kinematic models of the tissue can be used for comparison and identification of tissue.
Method of Monitoring Lesion Depth. As shown in
Step S400, which recites obtaining a standard lesion ratio, functions to generate a numerical value (the standard lesion ratio) that is associated with a transmural lesion. The standard lesion ratio further functions as a value to which other lesion ratios can be compared to assess if transmurality has been reached. Preferably, the standard lesion ratio is a normalized backscatter signal value of a transmural lesion. Alternatively, the standard lesion ratio may be a normalized signal pattern, a frequency, or any other signal property that is unique for a transmural lesion. Step S400 is preferably performed with two sub-steps including sensing a tissue backscatter signal with high echodensity S402, and sensing a tissue backscatter signal with low echodensity S404. The ratio of the tissue backscatter signal with high echodensity and the tissue backscatter signal with low echodensity preferably make up the standard lesion ratio. Alternatively, the standard lesion ratio may be a laboratory-determined value, which is preprogrammed into the processor, or any other suitable value.
Step S402, which recites sensing a tissue backscatter signal with high echodensity, functions to obtain a signal sample of tissue where a transmural lesion is present. Preferably, the sensor detects an ultrasound reflection from tissue with a transmural lesion. More preferably, the lesion results in increased backscatter and an attenuation of ultrasound. The amount of backscatter and attenuation preferably distinguish the tissue backscatter signal of ablated tissue from tissue that has not undergone ablation.
Step S404, which recites sensing a tissue backscatter signal with low echodensity, functions to obtain a signal sample of tissue that has not undergone ablation. Preferably, the sensor detects an ultrasound reflection from tissue that has not undergone ablation, but is of similar thickness to the high echodensity sample. Tissue of similar thickness may be obtained by scanning tissue with close proximity to that of the ablated tissue sample, tissue with similar wall motion, or identical location (but measuring the low echodensity signal before ablation occurs) or any other suitable combination of locations with similar tissue thicknesses. Alternatively, the sensor may detect an ultrasound reflection from a portion of tissue that was occluded (in a shadow) during ablation. In most situations, the tissue without a lesion has less backscatter and less attenuation of ultrasound than tissue with a lesion.
Step S410, which recites sensing initial tissue backscatter signal before ablation, functions to obtain the tissue backscatter signal with low echodensity for the current lesion ratio. Preferably, the signal is sensed right before ablation begins for a portion of tissue. Alternatively, the initial tissue backscatter signal may be obtained for all points during a diagnostic sweep of the tissue. As another alternative, the initial tissue backscatter signal may be sampled repeatedly during the ablation by sensing the tissue backscatter signal from tissue of close proximity, tissue occluded during ablation (in the beam shadow), or any other suitable location.
Step S420, which recites ablating tissue, functions to increase the lesion depth of the tissue by ablating the tissue in an incremental amount. Step S420 is preferably repeated several times during the course of the method. In a first variation, the ablation steps (i.e., the depth of ablation during one cycle of Step S410) incrementally add to approach transmurality of the tissue, moving from gross ablation steps to small ablation steps. During the first iteration of Step S420, the ablation of the tissue is such that transmurality is not expected, but the ablation step is large enough to ablate a significant portion of the tissue without over ablating the tissue. In further iterations, the ablation preferably approaches the state of transmurality in an approximately asymptotic manner; each step is a smaller ablation depth. The final iteration preferably achieves transmurality. Additionally, estimation of tissue thickness made by the sensor or from an outside source may be used to more efficiently determine ablation steps. In a second variation, each ablation step may be identical in size regardless of iteration or thickness estimation. As another alternative, ablation may occur continuously if Step S430 and Step S440 also occur continuously or periodically during the process.
Step S430, which recites sensing tissue backscatter signal of ablated tissue, functions to obtain the tissue backscatter signal with high echodensity for the current lesion ratio. The sensing of the tissue backscatter signal preferably occurs after each ablation step is completed and preferably occurs periodically or continuously. The sensing of the tissue backscatter signal may, however, occur at any other appropriate time.
Step S440, which recites comparing current lesion ratio to standard lesion ratio, functions to assess if transmurality has been reached. Preferably, the current lesion ratio is based on the initial tissue backscatter signal obtained in Step S410 and the tissue backscatter signal during ablation of Step S430. The current lesion ratio is then compared to the standard lesion ratio obtained in Step S400. If the current lesion ratio is less than the standard lesion ratio (i.e., transmurality has not been reached), ablation preferably continues and Steps S420, S430, and S440 are preferably repeated. If the values are equal (i.e., transmurality has been reached or exceeded), the process proceeds to Step S450. Alternatively, any suitable means of comparing the ratios may be used, including comparisons that do not rely upon actual ratios but rather other numerical values.
Step S450, which recites ceasing ablation when the current lesion ratio and the standard lesion ratio are equal (or within a predetermined threshold of equity), functions to end the ablation process for the tissue. After Step 450, the energy delivery system preferably moves to the next section of tissue to be ablated.
As a person skilled in the art will recognize from the previous detailed description and from the figures and claims, modifications and changes can be made to the preferred embodiments of the invention without departing from the scope of this invention defined in the following claims.
The present application is a continuation of U.S. patent application Ser. No. 14/947,294, filed Nov. 20, 2015, which is a continuation application of U.S. patent application Ser. No. 14/330,422 now U.S. Pat. No. 9,220,924, filed on Jul. 14, 2014 which is a continuation of U.S. patent application Ser. No. 13/630,697, filed Sep. 28, 2012, now abandoned, which is a continuation of U.S. patent application Ser. No. 12/609,759 now U.S. Pat. No. 9,033,885 filed Oct. 30, 2009, which is a non-provisional of, and claims the benefit of U.S. Provisional Application No. 61/109,873, filed Oct. 30, 2008; the entire contents of each are incorporated herein by reference. The present application is also related to U.S. Provisional Patent Application Nos. 61/110,905; 61/115,403; 61/148,809; 61/109,973; 61/109,875; 61/109,879; 61/109,881; 61/109,882; 61/109,889; 61/109,893; 61/254,997; and U.S. patent application Ser. Nos. 11/747,862; 11/747,867; 12/480,929; 12/480,256; 12/483,174; 12/482,640; 12/505,326; 12/505,335; the entire contents of which are incorporated herein by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4641649 | Walinsky et al. | Feb 1987 | A |
| 4757820 | Itoh | Jul 1988 | A |
| 5164920 | Bast et al. | Nov 1992 | A |
| 5246438 | Langberg | Sep 1993 | A |
| 5295484 | Marcus, I et al. | Mar 1994 | A |
| 5314466 | Stern et al. | May 1994 | A |
| 5405346 | Grundy et al. | Apr 1995 | A |
| 5471988 | Fujio et al. | Dec 1995 | A |
| 5588432 | Crowley | Dec 1996 | A |
| 5630837 | Crowley | May 1997 | A |
| 5718241 | Ben-Haim et al. | Feb 1998 | A |
| 5735811 | Brisken | Apr 1998 | A |
| 6012457 | Lesh | Jan 2000 | A |
| 6024740 | Lesh et al. | Feb 2000 | A |
| 6052576 | Lambourg | Apr 2000 | A |
| 6064902 | Haissaguerre et al. | May 2000 | A |
| 6117101 | Diederich et al. | Sep 2000 | A |
| 6161543 | Cox et al. | Dec 2000 | A |
| 6164283 | Lesh | Dec 2000 | A |
| 6237605 | Vaska et al. | May 2001 | B1 |
| 6245064 | Lesh et al. | Jun 2001 | B1 |
| 6245095 | Dobak, III et al. | Jun 2001 | B1 |
| 6251129 | Dobak, III et al. | Jun 2001 | B1 |
| 6251130 | Dobak, III et al. | Jun 2001 | B1 |
| 6254599 | Lesh et al. | Jul 2001 | B1 |
| 6261312 | Dobak, III et al. | Jul 2001 | B1 |
| 6267734 | Ishibashi et al. | Jul 2001 | B1 |
| 6277116 | Utely et al. | Aug 2001 | B1 |
| 6305378 | Lesh | Oct 2001 | B1 |
| 6311090 | Knowlton | Oct 2001 | B1 |
| 6311692 | Vaska et al. | Nov 2001 | B1 |
| 6314962 | Vaska et al. | Nov 2001 | B1 |
| 6314963 | Vaska et al. | Nov 2001 | B1 |
| 6379378 | Werneth et al. | Apr 2002 | B1 |
| 6383151 | Diederich et al. | May 2002 | B1 |
| 6387089 | Kreindel et al. | May 2002 | B1 |
| 6416511 | Lesh et al. | Jul 2002 | B1 |
| 6425867 | Vaezy et al. | Jul 2002 | B1 |
| 6468296 | Dobak, III et al. | Oct 2002 | B1 |
| 6474340 | Vaska et al. | Nov 2002 | B1 |
| 6475231 | Dobak et al. | Nov 2002 | B2 |
| 6478811 | Dobak, III et al. | Nov 2002 | B1 |
| 6478812 | Dobak et al. | Nov 2002 | B2 |
| 6484727 | Vaska et al. | Nov 2002 | B1 |
| 6491039 | Dobak, III | Dec 2002 | B1 |
| 6491716 | Dobak et al. | Dec 2002 | B2 |
| 6500121 | Slayton et al. | Dec 2002 | B1 |
| 6500174 | Maguire et al. | Dec 2002 | B1 |
| 6502576 | Lesh | Jan 2003 | B1 |
| 6514244 | Pope et al. | Feb 2003 | B2 |
| 6514249 | Maguire et al. | Feb 2003 | B1 |
| 6517536 | Hooven et al. | Feb 2003 | B2 |
| 6529756 | Phan et al. | Mar 2003 | B1 |
| 6533804 | Dobak et al. | Mar 2003 | B2 |
| 6540771 | Dobak et al. | Apr 2003 | B2 |
| 6542781 | Koblish et al. | Apr 2003 | B1 |
| 6546935 | Hooven | Apr 2003 | B2 |
| 6547788 | Maguire et al. | Apr 2003 | B1 |
| 6551349 | Lasheras et al. | Apr 2003 | B2 |
| 6576001 | Werneth et al. | Jun 2003 | B2 |
| 6585752 | Dobak et al. | Jul 2003 | B2 |
| 6592576 | Andrews et al. | Jul 2003 | B2 |
| 6595989 | Schaer | Jul 2003 | B1 |
| 6599288 | Maguire et al. | Jul 2003 | B2 |
| 6602276 | Dobak, III et al. | Aug 2003 | B2 |
| 6605084 | Acker et al. | Aug 2003 | B2 |
| 6607502 | Maguire et al. | Aug 2003 | B1 |
| 6607527 | Ruiz et al. | Aug 2003 | B1 |
| 6613046 | Jenkins et al. | Sep 2003 | B1 |
| 6635054 | Fjield et al. | Oct 2003 | B2 |
| 6645199 | Jenkins et al. | Nov 2003 | B1 |
| 6645202 | Pless et al. | Nov 2003 | B1 |
| 6648908 | Dobak et al. | Nov 2003 | B2 |
| 6652515 | Maguire et al. | Nov 2003 | B1 |
| 6652517 | Hall et al. | Nov 2003 | B1 |
| 6666614 | Fechter et al. | Dec 2003 | B2 |
| 6666858 | LaFontaine | Dec 2003 | B2 |
| 6669655 | Acker et al. | Dec 2003 | B1 |
| 6669687 | Saadat | Dec 2003 | B1 |
| 6676688 | Dobak et al. | Jan 2004 | B2 |
| 6676689 | Dobak et al. | Jan 2004 | B2 |
| 6676690 | Werneth | Jan 2004 | B2 |
| 6685732 | Kramer | Feb 2004 | B2 |
| 6689128 | Sliwa et al. | Feb 2004 | B2 |
| 6692488 | Dobak et al. | Feb 2004 | B2 |
| 6695873 | Dobak et al. | Feb 2004 | B2 |
| 6701931 | Sliwa et al. | Mar 2004 | B2 |
| 6702842 | Dobak et al. | Mar 2004 | B2 |
| 6711444 | Koblish | Mar 2004 | B2 |
| 6719755 | Sliwa et al. | Apr 2004 | B2 |
| 6745080 | Koblish | Jun 2004 | B2 |
| 6752805 | Maguire et al. | Jun 2004 | B2 |
| 6758847 | Maguire | Jul 2004 | B2 |
| 6763722 | Fjield et al. | Jul 2004 | B2 |
| 6780183 | Jimenez et al. | Aug 2004 | B2 |
| 6786218 | Dobak et al. | Sep 2004 | B2 |
| 6805128 | Pless et al. | Oct 2004 | B1 |
| 6805129 | Pless et al. | Oct 2004 | B1 |
| 6814733 | Schwartz et al. | Nov 2004 | B2 |
| 6840936 | Sliwa et al. | Jan 2005 | B2 |
| 6858026 | Sliwa et al. | Feb 2005 | B2 |
| 6869431 | Maguire et al. | Mar 2005 | B2 |
| 6872205 | Lesh et al. | Mar 2005 | B2 |
| 6889694 | Hooven | May 2005 | B2 |
| 6893438 | Hall et al. | May 2005 | B2 |
| 6896673 | Hooven | May 2005 | B2 |
| 6899710 | Hooven | May 2005 | B2 |
| 6899711 | Stewart et al. | May 2005 | B2 |
| 6904303 | Phan et al. | Jun 2005 | B2 |
| 6905494 | Yon et al. | Jun 2005 | B2 |
| 6905498 | Hooven | Jun 2005 | B2 |
| 6905509 | Dobak et al. | Jun 2005 | B2 |
| 6908464 | Jenkins et al. | Jun 2005 | B2 |
| 6920883 | Bessette et al. | Jul 2005 | B2 |
| 6923806 | Hooven et al. | Aug 2005 | B2 |
| 6923808 | Taimisto | Aug 2005 | B2 |
| 6929639 | LaFontaine | Aug 2005 | B2 |
| 6932811 | Hooven et al. | Aug 2005 | B2 |
| 6949095 | Vaska et al. | Sep 2005 | B2 |
| 6949097 | Stewart et al. | Sep 2005 | B2 |
| 6953460 | Maguire et al. | Oct 2005 | B2 |
| 6954977 | Maguire et al. | Oct 2005 | B2 |
| 6955173 | Lesh | Oct 2005 | B2 |
| 6964660 | Maguire et al. | Nov 2005 | B2 |
| 6966908 | Maguire et al. | Nov 2005 | B2 |
| 6971394 | Sliwa et al. | Dec 2005 | B2 |
| 6974454 | Hooven | Dec 2005 | B2 |
| 6984233 | Hooven | Jan 2006 | B2 |
| 6996908 | Orloff et al. | Feb 2006 | B2 |
| 6997925 | Maguire et al. | Feb 2006 | B2 |
| 7001378 | Yon et al. | Feb 2006 | B2 |
| 7001415 | Hooven | Feb 2006 | B2 |
| 7044135 | Lesh | May 2006 | B2 |
| 7063682 | Whayne et al. | Jun 2006 | B1 |
| 7142905 | Slayton et al. | Nov 2006 | B2 |
| 7275450 | Hirai et al. | Oct 2007 | B2 |
| 7282060 | DeBenedictis et al. | Oct 2007 | B2 |
| 7285116 | Rama et al. | Oct 2007 | B2 |
| 7306593 | Keidar et al. | Dec 2007 | B2 |
| 7393325 | Barthe et al. | Jul 2008 | B2 |
| 9033885 | Thapliyal et al. | May 2015 | B2 |
| 9155588 | Thapliyal et al. | Oct 2015 | B2 |
| 9220924 | Thapliyal et al. | Dec 2015 | B2 |
| 9833641 | Thapliyal et al. | Dec 2017 | B2 |
| 20020026118 | Govari | Feb 2002 | A1 |
| 20020087151 | Mody et al. | Jul 2002 | A1 |
| 20030050630 | Mody et al. | Mar 2003 | A1 |
| 20030050631 | Mody et al. | Mar 2003 | A1 |
| 20030171668 | Tsujino | Sep 2003 | A1 |
| 20040015065 | Panescu | Jan 2004 | A1 |
| 20040019447 | Shachar | Jan 2004 | A1 |
| 20050049582 | DeBenedictis et al. | Mar 2005 | A1 |
| 20050165388 | Bhola | Jul 2005 | A1 |
| 20050256518 | Rama et al. | Nov 2005 | A1 |
| 20050267453 | Wong et al. | Dec 2005 | A1 |
| 20060122508 | Slayton et al. | Jun 2006 | A1 |
| 20060135953 | Kania et al. | Jun 2006 | A1 |
| 20070027445 | Gifford et al. | Feb 2007 | A1 |
| 20070043296 | Schwartz | Feb 2007 | A1 |
| 20070265609 | Thapliyal et al. | Nov 2007 | A1 |
| 20070265610 | Thapliyal et al. | Nov 2007 | A1 |
| 20080039746 | Hissong et al. | Feb 2008 | A1 |
| 20080077200 | Bendett et al. | Mar 2008 | A1 |
| 20080287794 | Li | Nov 2008 | A1 |
| 20080287802 | Li | Nov 2008 | A1 |
| 20090312673 | Thapliyal et al. | Dec 2009 | A1 |
| 20090312693 | Thapliyal et al. | Dec 2009 | A1 |
| 20100016762 | Thapliyal et al. | Jan 2010 | A1 |
| 20100049099 | Thapliyal et al. | Feb 2010 | A1 |
| 20130096593 | Thapliyal et al. | Apr 2013 | A1 |
| 20140324085 | Thapliyal et al. | Oct 2014 | A1 |
| Number | Date | Country |
|---|---|---|
| 10037660 | Feb 2002 | DE |
| WO-9902096 | Jan 1999 | WO |
| WO-2005117734 | Dec 2005 | WO |
| WO-2006034000 | Mar 2006 | WO |
| WO-2005117734 | Dec 2006 | WO |
| Entry |
|---|
| A new treatment for atrial fibrillation? Feb. 2006, Medical Device & Diagnostic Industry, Medical Device Link, http://www.devicelink.com/mddi/archive/06/02/013.html (2 pgs.). |
| Bushberg, et al. The essential physics of medical imaging. 2nd Ed.; Lippincott Williams & Wilkins (2002) (p. 491). |
| Cox et al. Current status of the Maze procedure for the treatment of atrial fibrillation. Semin Thorac Cardiovasc Surg 12:15-19 (2000). |
| Cox et al. Electrophysiologic basis, surgical development, and clinical results of the maze procedure for atrial flutter and atrial fibrillation. Adv Card Surg 6:1-67 (1995). |
| Cox et al. Modification of the maze procedure for atrial flutter and atrial fibrillation. II, Surgical technique of the maze III procedure. J Thorac Cardiovasc Surg 110:485-495 (1995). |
| Cox et al. The development of the Maze procedure for the treatment of atrial fibrillation. Semin Thorac Cardiovasc Surg 12:2-14 (2000). |
| Gentry et al. Integrated Catheter for 3-D Intracardiac Echocardiography and Ultrasound Ablation. IEEE Trans Ultrason Ferroelectr Freq Control 51(7):800-808 (2004). |
| GILL. How to perform pulmonary vein isolation. Europace 6(2):83-91 (2004). |
| Gillinov et al. Atrial fibrillation: current surgical options and their assessment. Ann Thorac Surg 74:2210-2217 (2002). |
| Haissaguerre et al. Spontaneous Initiation of Atrial Fibrillation by Ectopic Beats Originating in the Pulmonary Veins. N Engl J Med 339:659-666 (1998). |
| Levinson. Endocardial Microwave Ablation: A New Surgical Approach for Atrial Fibrillation. The Heart Surgery Forum. (2006) (5 pgs). |
| Maessen et al. Beating heart surgical treatment of atrial fibrillation with microwave ablation. Ann Thorac Surg 74:1160-8 (2002). |
| Nathan et al. The junction between the left atrium and the pulmonary veins, an anatomic study of human hearts. Circulation 34:412-422 (1966). |
| Notice of allowance dated Mar. 10, 2015 for U.S. Appl. No. 12/609,759. |
| Notice of Allowance dated Jul. 27, 2017 for U.S. Appl. No. 14/947,294. |
| Notice of allowance dated Aug. 21, 2015 for U.S. Appl. No. 14/330,422. |
| Office action dated Jan. 14, 2014 for U.S. Appl. No. 13/630,697. |
| Office action dated Jan. 22, 2015 for U.S. Appl. No. 14/330,422. |
| Office Action dated Feb. 23, 2017 for U.S. Appl. No. 14/947,294. |
| Office action dated Mar. 26, 2012 for U.S. Appl. No. 12/609,759. |
| Office action dated Apr. 19, 2013 for U.S. Appl. No. 12/609,759. |
| Office action dated Aug. 12, 2014 for U.S. Appl. No. 12/609,759. |
| Office action dated Aug. 21, 2013 for U.S. Appl. No. 13/630,697. |
| Office action dated Sep. 4, 2013 for U.S. Appl. No. 12/609,759. |
| Office action dated Dec. 10, 2012 for U.S. Appl. No. 12/609,759. |
| Office action dated Dec. 18, 2013 for U.S. Appl. No. 12/609,759. |
| Pappone et al. Non-fluoroscopic mapping as a guide for atrial ablation: current status and expectations for the future. European Heart Journal Supplements. Dec. 2007; 9:1136-1147. |
| Sueda et al. Efficacy of a simple left atrial procedure for chronic atrial fibrillation in mitral valve operations. Ann Thorac Surg 63:1070-10751800 (1997). |
| Sueda et al. Simple left atrial procedure for chronic atrial fibrillation associated with mitral valve disease. Ann Thorac Surg 62:1796-1800 (1996). |
| Ter Haar. Acoustic surgery. Physics Today 54(12):29-34 (2001). |
| Number | Date | Country | |
|---|---|---|---|
| 20180043189 A1 | Feb 2018 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61109873 | Oct 2008 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14947294 | Nov 2015 | US |
| Child | 15790841 | US | |
| Parent | 14330422 | Jul 2014 | US |
| Child | 14947294 | US | |
| Parent | 13630697 | Sep 2012 | US |
| Child | 14330422 | US | |
| Parent | 12609759 | Oct 2009 | US |
| Child | 13630697 | US |
